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Summary External quality assurance (EQA) schemes
are essential for improvement of accuracy, reliability
and comparability of results of biochemical genetic
tests. ERNDIM (European Research Network for
evaluation and improvement of screening, Diagnosis
and treatment of Inherited disorders of Metabolism),
established in 1994, operates nine EQA schemes for
biochemical genetic testing according to international
norms and recommendations. These comprise qualita-
tive schemes for amino acids, organic acids, purines and
pyrimidines, special assays in serum and urine and white
cell cystine, qualitative organic acid and acylcarnitine
schemes, as well as diagnostic proficiency testing. The
total number of participants has increased from 123 in
1994 to 268 in 2007. Additional activities include
participation in the Eurogentest project, a laboratory
directory, training, education and development of
guidelines. Results from the quantitative amino acid
scheme with 170 participants reveal good variation
within and between laboratories of below 10% for 10
amino acids; good within-laboratory variation but
intermediate inter-laboratory variation of 10–22% for
11 amino acids; and higher variation within and
between laboratories for 8 amino acids. Results on
samples from 51 inherited metabolic disorders from two
of five centres organizing diagnostic proficiency testing
indicate overall diagnostic efficiency above 80% and
improved performance of individual laboratories. Com-
parison of results for 10 and 12 compounds in the serum
and urine special assay schemes respectively for 2000
and 2007 reveal clear improvement of precision within
laboratories and in inter-laboratory variation. There is
considerable evidence that performance in biochemi-
cal genetic testing has improved since the introduction
of ERNDIM schemes.
Abbreviations
DPT diagnostic proficiency testing
EQA external quality assurance
ERNDIM European Research Network for
evaluation and improvement of
screening, Diagnosis and treatment
of Inherited disorders of Metabolism
Introduction
Following advances in screening and treatment of phenyl-
ketonuria, technological advances such as quantitative
ion-exchange chromatography, gas chromatography cou-
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pled with mass spectrometry, high-performance liquid
chromatography and tandem mass spectrometry led to a
dramatic rise in the number of detected diseases involving
several different classes of compounds. Not only diagno-
sis but also monitoring of treatment demands precise
methods that need to be organized in order to serve all
potential patients at the national and international level
and to be performed by suitably trained staff. It is
necessary to raise the levels of accuracy, precision,
reproducibility and harmonization of laboratory testing
in this field, benefiting from experience of internal and
external quality control gathered in clinical chemistry
during the 1970s and 1980s. At the same time we need to
recognize that reliable diagnosis and treatment often
require biochemical analyses using highly specialized
techniques and equipment and require interpretation of
the results by experienced personnel. Further, the
reliability and validity of methods and comparability of
results is essential. This is especially important with the
evolution of agreed treatment thresholds of metabolite
levels in treated patients, the special need for consensus
cut-off values in newborn screening by tandem MS, and
also for meaningful comparison of results in multi-centre
studies. As mobility of families between countries
increases, it is essential that biochemical results can be
used for treatment of patients in another country
independently of where the analyses are performed.
EQA for biochemical genetic testing needs to be
provided on an international basis since the number of
provider laboratories in any individual country is far too
small for statistically meaningful evaluation of results
within an EQA scheme.
The ERNDIM (European Research Network for
evaluation and improvement of screening, Diagnosis
and treatment of Inherited disorders of Metabolism)
foundation was established in 1994 in order to meet
the challenges raised above. ERNDIM initially fo-
cused on the provision of external quality assurance
(EQA) schemes, recognizing its importance in relation
to accreditation of laboratories with the support of two
EU Biomed grants. Latterly, ERNDIM has become
engaged in wider issues relevant to provision of
biochemical genetic testing.
ERNDIM organizes EQA schemes according to
accepted norms on a mainly European-wide scale,
although several laboratories from outside Europe par-
ticipate. All schemes are operated according to guide-
lines summarized by Sciacovelli and colleagues (2001)
and are harmonized as much as possible with respect to
numbers and frequency of samples and submission of
results and receipt of reports by internet. Schemes are
provided by SKML (Stichting Kwaliteitsbewaking
Medische Laboratoriumdiagnostiek, Dutch Foundation
for Quality Assessment in Clinical Laboratories) or
academic centres. The scheme providers work closely
together with the Scientific Advisory Board and
schemes are administered by the ERNDIM executive
committee, which represents the ERNDIM Foundation
Board (see http://www.erndim.unibas.ch/pdf/ssiem_
structure.pdf for details of these bodies and the organi-
zation of ERNDIM).
In wider terms, ERNDIM aims to promote agree-
ment between European biochemical genetic testing
laboratories on reliable and standardized procedures for
diagnosis, treatment and monitoring of inherited meta-
bolic diseases. It also advances education through meet-
ings and by providing relevant documentation such as
guidance documents for the analysis of groups of metab-
olites and annual reports of EQA schemes on its web site.
ERNDIM aims to be financially self-sufficient
through minimal administration costs and efficient
subscription collection.
ERNDIM EQA schemes
The different ERNDIM schemes, centres operating
the schemes, year of establishment of the scheme and
initial and present participant numbers are summa-
rized in Table 1. Full details of the compounds
included in the schemes and numbers of samples
tested per year can be found at the ERNDIM website
(http://www.erndimqa.nl/InfoFrame.php).
As well as an increase in schemes, the total number
of participants has increased greatly from 123 in 1994
to 268 in 2007. Today ERNDIM offers nine different
schemes of three types as follows.
Quantitative schemes use samples in which variable
quantities of a range of metabolites are added to a
physiological matrix. For plasma, dialysed pooled
control samples are prepared; and for urine, pooled
samples from institutionalized subjects receiving a very
poor diet are used. Participant_s results are computed
to provide consensus values and to test accuracy,
recovery, precision and linearity for each laboratory
as well as to compare performance between laborato-
ries. In selecting the sample content, emphasis is given
to concentrations of clinical relevance including low as
well as high levels.
Qualitative proficiency schemes (organic acids, acyl-
carnitines) use natural samples from control or IEM
subjects and participants are required to analyse and
interpret the overall pattern of metabolites to make or
exclude a diagnosis. Attention is paid to the style of
reports, which should be made in the same way they
would be given to a nonspecialist paediatrician in a
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general hospital. The qualitative organic acid scheme
has been reported in detail in this issue of the Journal
(Peters et al 2008).
Diagnostic proficiency testing (DPT) schemes also
use patient urine samples. The DPT schemes are
limited to a maximum of 25 participants owing to the
difficulty of obtaining sufficient urine from patients
and also the need to create an intimate forum in which
results, including mistakes, can be discussed at the
annual meeting of participants.
This scheme is designed to assess test selection
based on clinical details provided, analytical perfor-
mance and interpretation of results and recommenda-
tions for further tests.
Results and experience for particular schemes
Quantitative amino acids
This scheme was briefly described by Fowler and
colleagues (2003a). It is the longest established scheme
and its main features also apply to other quantitative
schemes. Eight samples per year are prepared by
adding four different concentrations of each of 25
standard amino acids to lyophilized plasma in dupli-
cate. These amino acids are present every year,
allowing long-term comparison of performance. In
addition, four unusual amino acids are added each
year. Concentrations obtained for each amino acid are
submitted online through our web site and reports are
automatically produced for each sample for each
participant, showing the participant_s own values
compared with the median value for all laboratories.
Also the relationship of each value to all values is
shown graphically as the centile. Full details of all
results for each amino acid can be called up as shown
in Fig. 1. Comments can be added to the report by the
scientific advisor for the scheme. Results for all eight
samples are summarized in the annual report, which
shows: (1) accuracy as the average of the eight values;
(2) precision expressed as the coefficient of variation
for the four duplicate samples; (3) linearity and (4)
recovery, both calculated from the measured values
compared with the added quantities; and (5) the
coefficient of variation between all laboratories. It must
be borne in mind that reliable comparisons of variation
between laboratories in different years requires that
median values are similar in different years, that any
zero values are excluded, and that median and mean
values do not differ importantly. Table 2 shows the
median values for all laboratories and coefficient of
variation for the lowest, intermediate and highest
levels. Those obtained in 2002, the earliest year in
which low levels were provided, and in 2007 are shown
and results for each of the samples met the above
requirements for reliable comparisons. It is clearly
evident that variability between laboratories is greater
with lower than with high concentrations. Except for
some of the low levels there is maintenance of good
variability or some minor improvement over these
years. An example of the results in detail for an
individual amino acid, in this case phenylalanine, is
shown in Fig. 1. This example shows the values divided
according to gradations of 0.5 of the standard devia-
tion for each participant and indicates the methods
Table 1 Summary of ERNDIM external quality assurance schemes
ERNDIM QC scheme Sample type Year established Initial no.
participants
2007 no.
participants
Quantitative amino acids Physiological matrix plus standards 1994 88 200
Special assays in urine Physiological matrix plus standards 1994 Total 66 134
Special assays in serum Physiological matrix plus standards 1994 176
Quantitative organic
acids urine
Physiological matrix plus standards 1994 51 76
Purines and pyrimidines
in urine
Physiological matrix plus standards 2002 34 51
Cystine in white
blood cells
Cystine and protein in a white blood cell
extract matrix.
2004 23 27
Qualitative organic acids Authentic urine from patients 1994 38 159
Proficiency test divided
between 5 centres
Authentic urine from patients 1994 (Nijmegen)
1998 (Sheffield)
1998 (Lyon)
2001 (Prague)
2005 (Basel)
20 101
Acylcarnitines Blood from patients on filter paper 2003 47 75
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<344<-3SD
344 – 375-3 – -2SD
376 – 392-2.0 – -1.5SD
393 – 408-1.5 – -1.0SD
409 – 424-1.0 – -0.5SD
425 – 441-0.5 – 0SD
442 – 4570.0 – 0.5SD
458 – 4730.5 – 1.0SD
474 – 4901.0 – 1.5SD
491 – 5061.5 – 2.0SD
507 – 5402-3SD
>500>3SD
Scale
µmol/L
Scale
Standard
Deviations
Your lab
Reverse phase chromatography
IEC-ninhydrin-2 Internal Standards
Other GC or GC/MS
IEC-ninhydrin-1 Internal Standard
IEC-ninhydrin-0 Internal Standard
IEC-other derivatization
12 labs > 50 µmol/L above
consensus value
16 labs > 50 µmol/L below
consensus value
Fig. 1 Results in detail for phenylalanine with a consensus value of 442 mmol/L. IEC, ion-exchange chromatography; GC/MS, gas
chromatography–mass-spectrometry
Table 2 Performance in the amino acid scheme in 2002 and 2007
Amino acid Low level (mmol/L) Intermediate level (mmol/L) High level (mmol/L)
2002 2007 2002 2007 2002 2007
Median CV % Median CV % Median CV % Median CV % Median CV % Median CV %
a-Aminobutyric acid 6.0 40 6.0 23 9.7 21.4 9.9 10.4 25 14 29 11
Alanine 117 6.6 85 10 331 6.5 185 8.3 804 6.8 873 7.6
Arginine 19 16 9.7 23 219 8.4 220 8.0 301 8.5 362 7.6
Citrulline 12 19 10 17 110 10 99 8.8 151 9.1 494 8.0
Cystathionine 5.0 24 4.0 46 14.5 12.7 8 25 20 12 84 13
Cystine 9.5 22 27 15 37 12.2 53 10.2 49 8.8 72 10
Glycine 103 8.7 65 8.7 352 6.5 392 6.8 502 7.2 961 8.4
Histidine 33 14 46 9.4 104 10.4 102 9.9 146 9.2 427 9.5
Isoleucine 37 11 19 16 77 7.7 70 6.1 195 7.5 416 7.6
Leucine 75 9.9 52 9.8 302 7.2 355 6.7 421 6.9 1016 8.7
Lysine 87 8.6 60 8.9 158 8.5 145 8.7 346 7.4 531 6.7
Methionine 13 19 8.0 18 41 8.7 32 9.5 55 8.4 742 7.3
Ornithine 11 16 13 9.8 81 8.8 82 8.3 197 7.5 191 8.2
Phenylalanine 34 9.5 14 10 274 6.5 362 5.6 380 6.7 726 7.8
Sarcosine 33 27 46 22 195 12.3 237 10.9 485 12 714 14
Serine 26 12 9.0 25 77 7.3 54 9.4 195 7.1 166 7.5
Taurine 18 14 16 13 99 9.0 98 8.9 243 9.6 244 8.9
Threonine 33 9.4 33 8.9 87 7.2 85 8.3 207 6.2 297 6.7
Tyrosine 29 12 29 12 265 7.4 222 6.2 372 7.9 551 8.8
Valine 82 8.3 78 7.0 168 7.1 164 7.0 400 7.2 680 5.9
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used. Presently 138 out of the 170 laboratories that
submitted results used methods based on ion exchange
chromatography. The practical importance of analyti-
cal performance is clearly shown in this example. This
sample contained a phenylalanine concentration that is
similar to a value that might be used as a cut-off for
making decisions on changing the diet. With this
sample values at least 50 mmol/L higher or lower than
the consensus value were found by 12 and 16
laboratories respectively, with clear implications for
patient management and comparability of outcome in
relation to dietary control.
As a further indication of performance, the median
coefficient of variation within laboratories is compared
with variation between laboratories in Fig. 2. Data for
2006 are shown to allow illustration of performance
with some particular special amino acids. It must be
emphasized that these results have to be interpreted
with caution since they are based on comparison of
average median values for samples of low and high
concentrations that differ considerably. Nevertheless,
such limitations should apply equally to samples for
the years compared here. Generally, three groups of
amino acids are apparent: those with good precision
and inter-laboratory variation below 10%; those with
intermediate performance with good precision within
laboratories but inter-laboratory variation of 10–22%;
and those with poor precision above 16% and inter-
laboratory variation above 26%. Prior to this there
were few systematic data available on performance in
amino acid analysis. However, in 1990 amino acid
analysis performance within 27 UK laboratories was
reported (Rattenbury and Townsend 1990). Examples
of the coefficient of variation between laboratories for
individual amino acids in plasma compared with the
most recent ERNDIM values in brackets were as
follows: glycine 13% (8.1%); isoleucine 14% (10.5%);
phenylalanine 14% (8.1%); threonine 20% (8.2%);
arginine 22% (14.2%); and histidine 41% (9.5%). This
suggests a clear improvement of performance since the
introduction of the ERNDIM scheme.
Special assays for serum and urine
To illustrate performance achieved in the two special
assay schemes, results are shown for analytes consis-
tently included in the schemes for both serum and
urine from 2001 to 2007. The logistics of the schemes
are the same as those for the amino acid scheme.
Tables 3 and 4 show the median values for all labo-
ratories and coefficient of variation for the lowest,
intermediate and highest levels for results of 10 and 12
important diagnostic metabolites in the serum and
urine schemes respectively. Those obtained in 2001,
when the scheme took on its present format, and in
2007 are shown. There has been a substantial increase
in participation in both schemes. Returns for individ-
ual analytes ranged from 31 for 7-dehydrocholesterol
Amino acid QC scheme 2006: precision vs. interlab
variation
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Fig. 2 Comparison of
precision within laboratories
with inter-laboratory
variation for all amino
acids included in the amino
acid scheme in 2006. CV,
coefficient of variation; Ala,
alanine; Abu, a-aminobutyric
acid; Arg, arginine; Asn,
asparagine; Asp, aspartic
acid; Cit, citrulline; Cys,
cystine; Cysta, cystathionine;
Gln, glutamine; Glu, glutamic
acid; Gly, glycine; (Hcy)2,
homocystine; His, histidine;
1MeHis, 1-Me-histidine;
Hyp, hydroxyproline; Ile,
isoleucine; Leu, leucine; Lys,
lysine; Met, methionine; Orn,
ornithine; Phe, phenylalanine;
Pro, proline; Sar, sarcosine;
Ser, serine; S-Cys,
sulfocysteine; Tau, taurine;
Thr, threonine; Tyr, tyrosine;
Val, valine
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to 99 for homocysteine in 2001 and increased to 41 and
102 for these metabolites in 2007 for the serum
scheme. For the urine scheme, returns ranged from
8 for guanidino acetate to 73 for orotic acid in 2000
and from 21 for sialic acid to 93 for orotic acid in 2007.
As for amino acids, variability is clearly greater at
lower concentrations. For both the serum and urine
schemes there is improvement of variability over these
years for a number of metabolites. The urine scheme
has illuminated the importance of precision of creati-
nine measurements, since even moderate inaccuracies
can markedly effect the final results of metabolites
that have to be expressed in relation to creatinine, such
as organic acids.
In general this experience with the special assay
schemes provides clear evidence of improved perfor-
mance, although further improvements are clearly
needed for some compounds.
Diagnostic proficiency testing
In this scheme six samples per year from patients
with a specific inborn error of metabolism are circu-
lated by each of the five centres to participants in their
own scheme. One of these is a common sample sent
to all laboratories. Samples from subjects without an
inherited metabolic disorder (IMD) may also be
included. Participants receive some information on
Table 3 Comparison of overall performance in the special assays in serum scheme, 2001 and 2007
Compound Low level (mmol/L) Intermediate level (mmol/L) High level (mmol/L)
2001 2007 2001 2007 2001 2007
Median CV % Median CV % Median CV % Median CV % Median CV % Median CV %
3-OH-Butyric acid 80.5 37 46 50 1600 11 1635 11 4335 15 4560 13
7-Dehydrocholesterol 38 63 77 25 74 32 77 25 119 41 241 31
C22:0, Behemic acid 54 22 56 14 63 23 77 12 94 19 102 12
C24:0, Lignoceric acid 41 23 46 20 58 19 65 17 86 19 92 13
C26:0, Cerotic acid 0.475 55 0.52 32 3.3 24 3.7 16 9.0 28 9.8 15
Carnitine 32 11 36 14 66 11 67 12 128 11 132 9.2
Homocysteine (total) 11 8.5 12 10 43 11 48 8.2 106 11 117 8.7
Lactic acid 2310 11 2220 6.8 5725 7.1 4590 6.0 12700 9.0 9250 5.0
Phytanic acid 3.6 25 3.1 36 14 27 12 20 34 23 29 21
Pyruvic acid 49 32 66 20 540 32 365 16 1385 58 495 17
Table 4 Performance in the special assays in urine scheme in 2001 and 2007
Compound Low level (mmol/L) Intermediate level (mmol/L) High level (mmol/L)
2001 2007 2001 2007 2001 2007
Median CV % Median CV % Median CV % Median CV % Median CV % Median CV %
5-OH-Indoleacetic acid 4.3 22 2.2 58 38 23 37 14 102 29 105 18
Carnitine 20 13 16 23 54 11 17 10 67 13 462 12
Creatinine 2975 5.6 2740 5.5 6275 6.7 6180 5.8 12750 6.4 12800 5.7
Guanidino acetic acid 74 23 64 16 85 45 100 15 158 19 168 14
Homovanillic acid 5.8 34 2.9 47 38 19 35 21 110 14 102 23
Hydroxyproline 345 24 331 7.8 675 9.5 673 9.7 991 16 986 11
Lactic acid 3175 20 3200 12 6645 18 6470 15 9585 28 9515 14
Mucopolysaccharides 37 19 36 12 73 17 61 18 101 22 95 15
Orotic acid 7.5 46 30 12 13 32 57 13 20 30 81 16
Sialic acid 57 33 24 83 189 12 140 28 389 15 315 30
Succinylacetone 10 33 8.4 58 17 72 20 57 34 53 28 64
Uric acid 231 15 407 17 568 8.9 599 14 748 11 954 12
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the clinical presentation and treatment details if
applicable. They are required to perform any relevant
tests in order to reach a diagnosis and it is expected
that laboratories are able to perform tests for detection
of amino acid, organic acid, mucopolysaccharide
(MPS) and oligosaccharide disorders, and in some
schemes also for purine and pyrimidine disorders.
During recent years a harmonized scoring system has
been adopted by all five DPT centres. For each
sample, three criteria—analytical performance, inter-
pretative proficiency and recommendations for further
investigations—are evaluated and scored to give a
maximum of 5 points per sample. In the absence of any
results, the sample is scored as 0 points.
Satisfactory analytical performance (2 points)
depends on clearly described and correct analytical
results, which may be semi-quantitative evaluation of
an abnormal level of metabolite(s) or quantitative
value(s) or a description of a profile of analytes sug-
gestive of or excluding a specific diagnosis. Analytical
results may be considered only partially correct (1 point)
if incomplete procedures have been performed (e.g.
quantitative mucopolysaccharide measurement without
performing profile analysis of MPS), or if the results
are insufficiently specific. Zero points are given if the
appropriate test has not been carried out, or an elevated
metabolite has not been detected, or a decreased or
absent metabolite has been reported.
Satisfactory interpretative proficiency (2 points) is
judged as a correct diagnostic conclusion that is
achievable by analysing urine and may be a single
possible diagnosis or several diagnoses (e.g. methyl-
malonic aciduria due to mutase deficiency or cobalamin
defects or secondary to vitamin B12 deficiency). Helpful
but incomplete diagnostic conclusions (1 point) should
eventually lead to establishing the diagnosis, usually
pointing to a group of diseases (e.g. diagnosis of
mucopolysaccharidosis in the case of elevated MPS but
without a clearly described profile or with assignment of
a wrong type of MPS disorder). Wrong/misleading
diagnosis (0 points) can be Fover-diagnosis_ in the case
of no known IMD, completely inappropriate diagnosis,
or missed diagnosis in a patient with a known IMD.
Recommendations for further investigations should
be unambiguous and avoid redundancy of recommen-
dations, detachment from practice (tests that will not
be ordered in a real patient), non-specificity of
recommendations, or over-invasive testing in cases of
samples from patients with no IMDM.
To illustrate the level of performance within these
schemes, results obtained since 2001 for the Lyon and
Prague schemes, which were the first centres to
introduce a harmonized scoring system can be consid-
ered (Table 5).
Samples from 51 different inherited metabolic dis-
orders were included, those from 12 different disorders
on more than one occasion (2–4 times). Also, one sam-
ple is distributed by both centres each year. Full details
of these samples can be found in Supplementary
Table S1 accessible on-line. Efficiency of performance
as the percentage of correct results for all participants
for the sum of analytical and interpretative perfor-
mance and recommended investigations is just over
80% on average for all samples. Relatively poor
performance of between 28% and 69% efficiency was
found for samples from patients with a range of
disorders, in order of increasing efficiency as follows:
adenylosuccinate lyase deficiency, mucopolysacchari-
dosis type III, sialidosis, a patient with both adenine
phosphoribosyltransferase deficiency and MPS type
IV, molybdenum cofactor deficiency, aspartylglucosa-
minuria, isolated sulfite oxidase deficiency, biotinidase
deficiency, aromatic amino acid decarboxylase deficien-
cy, septic shock, peroxisomal disorder, fucosidosis, and
MPS type VII. All samples for which good performance
of over 90% efficiency was found came from patients
with an amino acid or organic acid disorder, although
performance was not satisfactory for all samples for
these types of disorder. For 11 samples that were dis-
tributed in different years, efficiency of performance
remained over 90% for four, showed no important
change in four and improved in three of them. Overall
trends in performance over the years are difficult to
evaluate owing to the use of widely differing samples,
but there has been a clear drop in the number of labo-
ratories judged to have performed poorly, as shown in
Table 5. The experience from the Sheffield scheme was
briefly reported by Bonham (2003).
Future developments of EQA schemes
Much progress has already been made in improving
performance in biochemical genetic testing, but further
improvement is still necessary. Steps to improve per-
formance include educational activities (see below),
Table 5 Numbers of poor performers related to numbers of
participants in the Prague and Lyon DPT schemes
2001 2002 2003 2004 2005 2006 2007
Prague 2/21 1/20 3/20 1/20 0/24 3/18 0/17
Lyon 6/17 2/20 2/20 0/22 0/19 0/22
Total 7/37 5/40 3/40 0/46 3/37 0/39
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provision of expert guidance papers on quality issues
and specific methods and development of reference
materials and calibrators. The recently published com-
prehensive book on methods for biochemical genetic
testing (Blau et al 2008) could be a valuable aid in
standardizing procedures.
Scoring and assessment of performance are an
essential part of an EQA scheme and needs to be har-
monized in order to define good performance. Steps are
currently under way for our schemes, and from 2007
certificates of participation for the individual laborato-
ries will include indicators of performance achieved.
Laboratories that fail to reach a satisfactory level of
performance are issued with a Fwarning_ letter, which is
in fact a Fhelping_ letter that is meant to initiate dialogue
on identification of problems and their remedies.
An essential development is to allow web-site
submission of results and on-line reporting, presently
available only for quantitative schemes, for all schemes.
Moves are now underway to develop web-site submis-
sions for the DPT and other qualitative schemes.
As well as encouragement of accreditation of the
participating laboratories, the EQA schemes them-
selves will need to be accredited and this demands
close cooperation with professionally operated EQA
providers such as SKML and possibly others. Beyond
this, moves have begun to towards accreditation of
ERNDIM itself. Thus, the way is clear to bring our
scheme into line with international requirements for
EQA schemes within the context of accreditation of
individual laboratories themselves.
Pilot schemes
To meet expanding needs, ERNDIM supports the
development of new schemes. First, potential scheme
organizers and scientific advisors need to ascertain the
potential need; 25 participants is the very lowest figure
possible, since the involvement of fewer does not allow
reliable statistical ascertainment of results. Second,
feasibility of the scheme needs to be proved during a
pilot phase, which usually lasts for two years. Sample
suitability, stability, robustness of result presentation
and reporting can all be tested. Then a new scheme
can be incorporated as an official ERNDIM scheme.
Presently two pilot schemes are underway. A scheme
for lysosomal enzymes, organized by SKML with
Dr O. van Diggelen as scientific advisor, was begun
in 2007. A new scheme for disorders of glycosylation
has been operated by SKML together with Professor
R. Wevers in 2008.
Other ERNDIM activities
Training and education
Since its inception, ERNDIM has been active in this
area and from an early stage workshops on diagnostic
issues have been organized at the SSIEM annual
symposium. Since 2001 these have been held following
the parallel meetings for the DPT participants and are
open to all persons attending the SSIEM symposium.
They address clinical pointers and analytical proce-
dures and performance in relevant ERNDIM schemes
for a particular group of disorders. Topics since 2000
have been amino acids, mucopolysaccharides, organic
acids, general aspects of schemes (Fowler et al 2003b),
acylcarnitines, purines and pyrimidines, lysosomal
enzymes (held at a separate ERNDIM meeting in
2006), peroxisomal disorders and creatine synthesis
disorders. These workshops provide the basis for
guidance documents on general issues of quality as
well as analysis of specific groups of metabolites.
These are mounted on the ERNDIM web site (http:
//www.erndim.unibas.ch/ FTraining and Education_ and
currently include: Theoretical Aspects of QC in IEM
and Method Validation; Control of Accuracy and
Precision; Amino Acid Analysis Recommendations;
Biomed 2 Recommendations; Polymorphonuclear
Leukocyte Preparation; Mixed Leukocyte Preparation;
White Cell Cystine Determination and the role of
EQA; and Role of EQA in Special Assays for IEM.
Further planned documents include recommendations
for analysis of organic acids, mucopolysaccharides,
purines/pyrimidines, lysosomal enzymes, acylcarni-
tines, and performance assessment in ERNDIM diag-
nostic proficiency schemes.
ERNDIM endeavours to support the training of
biochemists in biochemical genetic testing, similar to
that existing for paediatricians in metabolic medicine.
It is clear that training programmes will inevitably vary
between countries. This is a natural consequence of
the differences in professional and institutional envi-
ronments. It will also reflect genetic variation and the
differing geographic incidence of individual diseases.
However, there are many principles of good practice
and analytical techniques in common that we can learn
from each other. There is also much that countries
that plan to develop these services can learn from
those where they are well established. Accordingly,
ERNDIM has developed an area of its web site as a
resource where information can be sought about exist-
ing training programmes and web-based resources
can be shared. The web site provides a place for infor-
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mation on the approaches to training in each individual
country. Also, some training resources, such as the
training syllabus approved by SSIEM, the MetBioNet
training log, information about the French training
scheme, and a metabolic map, are directly available
from this site.
A new training initiative is to provide training days
for laboratory workers in collaboration with the
SSIEM and under the aegis of Education and Training
Advisory Committee. The first one-day course in
parallel with one for clinicians preceded the annual
SSIEM symposium at Lisbon in 2008.
ERNDIM/Eurogentest directory of laboratories
This has been established with support of a previous
EU project and currently within the Eurogentest
project. The aim of the directory is to aid specialist
workers in the field in selection of laboratories for
sample referral. Provision of information on quality
management such as accreditation status and partici-
pation in EQA schemes helps users to judge the
suitability of laboratories to which samples are sent.
Tests, referred to as analytes, for single or groups of
metabolites, enzyme activity and mutation analysis are
included. In using the directory, a specific analyte is
chosen from the pull-down list and laboratories
providing the service are listed, first from a specified
country followed by other countries. Details of the
listed laboratories are found under Fmore info_ accord-
ing to country with details on the laboratory including
contacts, general description, metabolic clinic, EQA
schemes participated in, accreditation status and
special interests.
Laboratories wishing to register their services within
the directory apply by submitting their details directly
to the web site. Subject to approval of the laboratory
by ERNDIM, the laboratory details are automatically
entered into the web site and a password is issued to
the laboratory by e-mail allowing entry to the FExisting
Participants_ area of the site. Existing participants can
enter this area in order to add or delete analytes they
perform as well as to update laboratory information.
The directory presently contains about 130 laborato-
ries for which information has been fully validated.
Currently about 480 analytes or tests are listed.
Approximately 200 additional European laboratories
that perform biochemical genetic testing have been
identified and encouraged to join the directory.
Further developments will be to link this directory to
the Eurogentest QAu database and to the disease-
oriented Orphanet web site.
Our aim is to increase awareness of quality issues in
the minds of users of biochemical genetic testing
services when they select the laboratories to which
they send samples. Ultimately we should all look at
the ERNDIM laboratory directory and check EQA
participation before sending out samples.
The Eurogentest Project and the role of ERNDIM
The Eurogentest project aims to promote the proper
utilization and management of genetic services; har-
monization of accreditation and certification of genetic
testing laboratories (http://www.eurogentest.org/); and
establishment of procedures and guidelines for the
validation of methods and technologies.
ERNDIM represents biochemical genetic testing
within the project (http://www.eurogentest.org/web/
info/unit1/biochemical.xhtml) and is currently engaged
in the following activities within the work packages 1.5
and 1.9. Specific aims are to expand opportunities for
biochemical genetic testing laboratories in the EU to
participate in EQA and to link this through agreed
best practice in internal and external quality control to
improve the quality of biochemical genetic testing.
Examples of achievements so far are as follows:
& Production of an interim report on biochemical
genetic testing in Europe: deficits and needs and
EQA. This report is based on two meetings with
national representatives from each EU country,
held in Basel, 2 December 2005 and Prague, 5–6
October 2006 (see http://www.erndim.unibas.ch/
Meeting_Rep/06_dec_basel/Best%20practice%20
EUGT%20UPDATED%20report%203Sept2007.
pdf).
& In order to expand the capacity and scope of our
schemes, a fifth diagnostic proficiency testing EQA
scheme has been established in Basel and two new
schemes for lysosomal enzymes and congenital
disorders of glycosylation are under development.
& We have developed criteria for performance assess-
ment of both proficiency and quantitative schemes
within best-practice meetings of the ERNDIM
Scientific Advisory and Executive Committees.
& Several educational activities have been consoli-
dated as mentioned above.
& The new ERNDIM web site has been developed,
including the directory of laboratories and training
and methodological guidance documents.
Meetings have been held together with our partners
responsible for EQA in cytogenetics and molecular
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genetics and accreditation experts in order to promote
accreditation of individual genetic EQA schemes as
well as EQA umbrella organizations. Resulting docu-
mentation includes checklists and quality manuals to
aid us all in the accreditation process.
Future plans include further best-practice meetings
with all EU national representatives to establish
guidelines for organization of biochemical genetic
testing services at the national level.
Conclusion
There is ample evidence that ERNDIM has fulfilled its
early aims of improvement of patient services and is
now synonymous with EQA for biochemical genetic
testing in Europe. Nevertheless, challenges remain to
continue to improve performance of laboratories and
to increase awareness by users of biochemical genetic
testing services of the importance of EQA. Introduc-
tion of measures highlighted above and increasing
cooperation with other genetic disciplines and the
SSIEM should help to sustain our important activities
in the future.
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